Vigil Neuroscience (NASDAQ:VIGL): A Precision Approach to NeLooks like a promising play in the neuro space. VIGL's TREM2 agonist approach for rare neurodeg diseases is intriguing. Phase 2 IGNITE trial data looking solid with clear target engagement. $51.99M cash runway into 2026 gives them runway to advance pipeline. Sanofi's $40M strategic investment adds credibility. Watching closely. BeyondSPX continues to deliver high quality in-depth analysis on just about every US stock out there, even microcaps, for free. Great resource for DD.Might take a small position if Phase 2 data continues to look promising. Neurodeg market is massive if they can crack the code. https://beyondspx.com/article/vigil-neuroscience-nasdaqvigl-a-precision-approach-to-neurodegenerative-disease